Literature DB >> 23946458

Deep-sequencing analysis of the association between the quasispecies nature of the hepatitis C virus core region and disease progression.

Mika Miura1, Shinya Maekawa, Shinichi Takano, Nobutoshi Komatsu, Akihisa Tatsumi, Yukiko Asakawa, Kuniaki Shindo, Fumitake Amemiya, Yasuhiro Nakayama, Taisuke Inoue, Minoru Sakamoto, Atsuya Yamashita, Kohji Moriishi, Nobuyuki Enomoto.   

Abstract

Variation of core amino acid (aa) 70 of hepatitis C virus (HCV) has been shown recently to be closely correlated with liver disease progression, suggesting that the core region might be present as a quasispecies during persistent infection and that this quasispecies nature might have an influence on the progression of disease. In our investigation, the subjects were 79 patients infected with HCV genotype 1b (25 with chronic hepatitis [CH], 29 with liver cirrhosis [LC], and 25 with hepatocellular carcinoma [HCC]). Deep sequencing of the HCV core region was carried out on their sera by using a Roche 454 GS Junior pyrosequencer. Based on a plasmid containing a cloned HCV sequence (pCV-J4L6S), the background error rate associated with pyrosequencing, including the PCR procedure, was calculated as 0.092 ± 0.005/base. Deep sequencing of the core region in the clinical samples showed a mixture of "mutant-type" Q/H and "wild-type" R at the core aa 70 position in most cases (71/79 [89.9%]), and the ratio of mutant residues to R in the mixture increased as liver disease advanced to LC and HCC. Meanwhile, phylogenetic analysis of the almost-complete core region revealed that the HCV isolates differed genetically depending on the mutation status at core aa 70. We conclude that the core aa 70 mixture ratio, determined by deep sequencing, reflected the status of liver disease, demonstrating a significant association between core aa 70 and disease progression in CH patients infected with HCV genotype 1b.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23946458      PMCID: PMC3838162          DOI: 10.1128/JVI.00826-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

Review 1.  Molecular basis of hepatitis C virus-associated hepatocarcinogenesis: lessons from animal model studies.

Authors:  Kazuhiko Koike
Journal:  Clin Gastroenterol Hepatol       Date:  2005-10       Impact factor: 11.382

2.  Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.

Authors:  Norio Akuta; Fumitaka Suzuki; Yusuke Kawamura; Hiromi Yatsuji; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

3.  Accurate determination of microbial diversity from 454 pyrosequencing data.

Authors:  Christopher Quince; Anders Lanzén; Thomas P Curtis; Russell J Davenport; Neil Hall; Ian M Head; L Fiona Read; William T Sloan
Journal:  Nat Methods       Date:  2009-08-09       Impact factor: 28.547

4.  Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

Authors:  Masao Honda; Akito Sakai; Tatsuya Yamashita; Yasunari Nakamoto; Eishiro Mizukoshi; Yoshio Sakai; Taro Yamashita; Mikiko Nakamura; Takayoshi Shirasaki; Katsuhisa Horimoto; Yasuhito Tanaka; Katsushi Tokunaga; Masashi Mizokami; Shuichi Kaneko
Journal:  Gastroenterology       Date:  2010-04-29       Impact factor: 22.682

5.  IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes.

Authors:  Pierre-Yves Bochud; Stéphanie Bibert; Zoltán Kutalik; Etienne Patin; Julien Guergnon; Bertrand Nalpas; Nicolas Goossens; Lorenz Kuske; Beat Müllhaupt; Tillman Gerlach; Markus H Heim; Darius Moradpour; Andreas Cerny; Raffaele Malinverni; Stephan Regenass; Guenter Dollenmaier; Hans Hirsch; Gladys Martinetti; Meri Gorgiewski; Marc Bourlière; Thierry Poynard; Ioannis Theodorou; Laurent Abel; Stanislas Pol; Jean-François Dufour; Francesco Negro
Journal:  Hepatology       Date:  2011-12-16       Impact factor: 17.425

6.  IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC.

Authors:  Carlo Fabris; Edmondo Falleti; Annarosa Cussigh; Davide Bitetto; Elisabetta Fontanini; Sara Bignulin; Sara Cmet; Ezio Fornasiere; Elisa Fumolo; Stefano Fangazio; Andrea Cerutti; Rosalba Minisini; Mario Pirisi; Pierluigi Toniutto
Journal:  J Hepatol       Date:  2010-09-19       Impact factor: 25.083

7.  Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.

Authors:  Norio Akuta; Fumitaka Suzuki; Miharu Hirakawa; Yusuke Kawamura; Hitomi Sezaki; Yoshiyuki Suzuki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Med Virol       Date:  2011-06       Impact factor: 2.327

8.  Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C.

Authors:  Mika Miura; Shinya Maekawa; Makoto Kadokura; Ryota Sueki; Kazuki Komase; Hiroko Shindo; Takako Ohmori; Asuka Kanayama; Kuniaki Shindo; Fumitake Amemiya; Yasuhiro Nakayama; Takatoshi Kitamura; Tomoyoshi Uetake; Taisuke Inoue; Minoru Sakamoto; Shunichi Okada; Nobuyuki Enomoto
Journal:  Hepatol Int       Date:  2011-08-17       Impact factor: 6.047

9.  Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

Authors:  C Niederau; S Lange; T Heintges; A Erhardt; M Buschkamp; D Hürter; M Nawrocki; L Kruska; F Hensel; W Petry; D Häussinger
Journal:  Hepatology       Date:  1998-12       Impact factor: 17.425

10.  Sequence requirements for the development of a chimeric HCV replicon system.

Authors:  Adam T Gates; Robert T Sarisky; Baohua Gu
Journal:  Virus Res       Date:  2004-03-15       Impact factor: 3.303

View more
  17 in total

1.  Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.

Authors:  Mitsuaki Sato; Shinya Maekawa; Nobutoshi Komatsu; Akihisa Tatsumi; Mika Miura; Masaru Muraoka; Yuichiro Suzuki; Fumitake Amemiya; Shinichi Takano; Mitsuharu Fukasawa; Yasuhiro Nakayama; Tatsuya Yamaguchi; Tomoyoshi Uetake; Taisuke Inoue; Tadashi Sato; Minoru Sakamoto; Atsuya Yamashita; Kohji Moriishi; Nobuyuki Enomoto
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

2.  Modulation of flavivirus population diversity by RNA interference.

Authors:  Doug E Brackney; Erin E Schirtzinger; Thomas D Harrison; Gregory D Ebel; Kathryn A Hanley
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

3.  Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA.

Authors:  Norio Akuta; Fumitaka Suzuki; Masahiro Kobayashi; Hitomi Sezaki; Yusuke Kawamura; Tetsuya Hosaka; Mariko Kobayashi; Satoshi Saitoh; Yoshiyuki Suzuki; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Clin Microbiol       Date:  2015-07-01       Impact factor: 5.948

Review 4.  Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma.

Authors:  Virginia Sedeno-Monge; Veronica Vallejo-Ruiz; Francisca Sosa-Jurado; Gerardo Santos-Lopez
Journal:  J Biosci       Date:  2017-09       Impact factor: 1.826

5.  A deep sequencing reveals significant diversity among dominant variants and evolutionary dynamics of avian leukosis viruses in two infectious ecosystems.

Authors:  Fanfeng Meng; Xuan Dong; Tao Hu; Shuang Chang; Jianhua Fan; Peng Zhao; Zhizhong Cui
Journal:  BMC Vet Res       Date:  2016-12-19       Impact factor: 2.741

Review 6.  Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy.

Authors:  Maria Victoria Preciado; Pamela Valva; Alejandro Escobar-Gutierrez; Paula Rahal; Karina Ruiz-Tovar; Lilian Yamasaki; Carlos Vazquez-Chacon; Armando Martinez-Guarneros; Juan Carlos Carpio-Pedroza; Salvador Fonseca-Coronado; Mayra Cruz-Rivera
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

7.  A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene.

Authors:  Ahmed El-Shamy; Francis J Eng; Erin H Doyle; Arielle L Klepper; Xiaochen Sun; Angelo Sangiovanni; Massimo Iavarone; Massimo Colombo; Robert E Schwartz; Yujin Hoshida; Andrea D Branch
Journal:  J Hepatol       Date:  2015-07-26       Impact factor: 25.083

8.  Analysis of direct-acting antiviral-resistant hepatitis C virus haplotype diversity by single-molecule and long-read sequencing.

Authors:  Kozue Yamauchi; Mitsuaki Sato; Leona Osawa; Shuya Matsuda; Yasuyuki Komiyama; Natsuko Nakakuki; Hitomi Takada; Ryo Katoh; Masaru Muraoka; Yuichiro Suzuki; Akihisa Tatsumi; Mika Miura; Shinichi Takano; Fumitake Amemiya; Mitsuharu Fukasawa; Yasuhiro Nakayama; Tatsuya Yamaguchi; Taisuke Inoue; Shinya Maekawa; Nobuyuki Enomoto
Journal:  Hepatol Commun       Date:  2022-03-31

9.  Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance.

Authors:  Norio Akuta; Fumitaka Suzuki; Hitomi Sezaki; Masahiro Kobayashi; Shunichiro Fujiyama; Yusuke Kawamura; Tetsuya Hosaka; Mariko Kobayashi; Satoshi Saitoh; Yoshiyuki Suzuki; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Clin Microbiol       Date:  2019-01-02       Impact factor: 5.948

10.  Amino Acid Polymorphisms in Hepatitis C Virus Core Affect Infectious Virus Production and Major Histocompatibility Complex Class I Molecule Expression.

Authors:  Megumi Tasaka-Fujita; Nao Sugiyama; Wonseok Kang; Takahiro Masaki; Takahiro Masaski; Asako Murayama; Norie Yamada; Ryuichi Sugiyama; Senko Tsukuda; Koichi Watashi; Yasuhiro Asahina; Naoya Sakamoto; Takaji Wakita; Eui-Cheol Shin; Takanobu Kato
Journal:  Sci Rep       Date:  2015-09-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.